Evidence map›Paper›PMID 33642398›Full record

ArticleNeural regeneration research2021

Markers for neural degeneration and regeneration: novel highly sensitive methods for the measurement of thrombin and activated protein C in human cerebrospinal fluid.

Alexandra Gerasimov, Valery Golderman, Shany Guly Gofrit, Shay Anat Aharoni, Daniela Noa Zohar, Ze'ev Itsekson-Hayosh, Tsviya Fay-Karmon, Sharon Hassin-Baer, Joab Chapman, Nicola Maggio and 1 more

Open access · goldAbstract read
In one paragraph

Article in Neural regeneration research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Alexandra GerasimovDepartment of Neurology, The Chaim Sheba Medical Center, Ramat Gan, Israel.
Valery GoldermanDepartment of Neurology and Neurosurgery, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Shany Guly GofritDepartment of Neurology, The Chaim Sheba Medical Center, Ramat Gan, Israel.
Shay Anat AharoniDepartment of Neurology, The Chaim Sheba Medical Center, Ramat Gan, Israel.
Daniela Noa ZoharDepartment of Neurology, The Chaim Sheba Medical Center, Ramat Gan, Israel.
Ze'ev Itsekson-HayoshDepartment of Neurology, The Chaim Sheba Medical Center, Ramat Gan, Israel.
Tsviya Fay-KarmonDepartment of Neurology; The Movement Disorders Institute, Chaim Sheba Medical Center, Ramat Gan, Israel.
Sharon Hassin-BaerDepartment of Neurology, The Chaim Sheba Medical Center, Ramat Gan; Department of Neurology and Neurosurgery, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv; The Movement Disorders Institute, Chaim Sheba Medical Center, Ramat Gan; Sagol School of Neuroscience, Tel Aviv University, Tel Aviv, Israel.
Joab ChapmanDepartment of Neurology, The Chaim Sheba Medical Center, Ramat Gan; Department of Neurology and Neurosurgery, Sackler Faculty of Medicine; Sagol School of Neuroscience; Department of Physiology and Pharmacology, Sackler Faculty of Medicine; Robert and Martha Harden Chair in Mental and Neurological Diseases, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Nicola MaggioDepartment of Neurology, The Chaim Sheba Medical Center, Ramat Gan; Department of Neurology and Neurosurgery, Sackler Faculty of Medicine; Sagol School of Neuroscience, Tel Aviv University, Tel Aviv; Talpiot Medical Leadership Program, The Chaim Sheba Medical Center, Ramat Gan, Israel.
Efrat Shavit-SteinDepartment of Neurology, The Chaim Sheba Medical Center, Ramat Gan; Department of Neurology and Neurosurgery, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Sheba Medical Center · ILTel Aviv University · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inflammation and coagulation are tightly interconnected in the pathophysiology of neuronal diseases. Thrombin, a pro-coagulant serine protease is associated with neurodegeneration and its indirect inhibitor, activated protein C (aPC), is considered neuroprotective. While levels of thrombin and aPC activity are readily measured in the blood, similar assays in the cerebrospinal fluid (CSF) have not been described. The aim of this study was to establish a specific and sensitive enzymatic assay to measure both thrombin and aPC activity in the CSF. CSF was collected from 14 patients with suspected normal pressure hydrocephalus served as a control group, while seven patients with central nervous system infections served as an acute neuro-inflammatory study group and one sample of CSF following traumatic lumbar puncture served as a positive control. Thrombin and aPC activities were measured by fluorescence released by specific proteolytic cleavage in the presence of endopeptidase and amino-peptidase inhibitors to ensure specificity. Specificity of the method was verified by thrombin and serine-protease inhibitors N-alpha-((2-naphthylsulfinyl)glycyl)-DL-p-amidinophenylalanylpiperidine and phenylmethanesulfonyl fluoride. Inhibition of thrombin activity by CSF samples and levels of specific thrombin inhibitors were also assessed. Thrombin and aPC activities were reliably measured and were significantly higher in the CSF of patients with central nervous system infections compared to normal pressure hydrocephalus controls, suggesting the involvement of these factors in neuro-inflammation. CSF thrombin activity levels in the presence of known thrombin concentration were high in patients with central nervous system infections, and low in normal pressure hydrocephalus patients. Quantification of endogenous thrombin inhibitors protease nexin 1, amyloid precursor protein and anti-thrombin III in CSF by western blot indicated a significant elevation of amyloid precursor protein in infectious CSF. In conclusion, this study describes a novel and sensitive assay aimed at the detection of thrombin and aPC activity in CSF. This method may be useful for measuring these factors that reflect degenerative and protective influences of coagulation on neurological disorders. The study procedure was approved by the Ethics Committee of the Chaim Sheba Medical Center (approval No. 4245-17-SMC) on October 18, 2018.

Indexed as

activated protein Ccerebrospinal fluidinfectioninflammationnormal pressure hydrocephalusthrombin

Identifiers

PMID33642398
PMCPMC8343305
OpenAlexW3131152496

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.